DK2018165T3 - Dimere agonistforbindelser af FGF-receptorer - Google Patents

Dimere agonistforbindelser af FGF-receptorer

Info

Publication number
DK2018165T3
DK2018165T3 DK07717861.4T DK07717861T DK2018165T3 DK 2018165 T3 DK2018165 T3 DK 2018165T3 DK 07717861 T DK07717861 T DK 07717861T DK 2018165 T3 DK2018165 T3 DK 2018165T3
Authority
DK
Denmark
Prior art keywords
dimeric
agonist compounds
fgf receptors
fgf
receptors
Prior art date
Application number
DK07717861.4T
Other languages
English (en)
Inventor
Pierre Fons
Jacob-Alsboek Olsen
Gilles Anne-Archard
Francoise Bono
Nathalie Guillo
Jean-Pierre Maffrand
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of DK2018165T3 publication Critical patent/DK2018165T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK07717861.4T 2006-01-13 2007-01-12 Dimere agonistforbindelser af FGF-receptorer DK2018165T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0600317A FR2896247B1 (fr) 2006-01-13 2006-01-13 Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
PCT/FR2007/000051 WO2007080325A1 (fr) 2006-01-13 2007-01-12 Composes dimeres agonistes des recepteurs des fgfs

Publications (1)

Publication Number Publication Date
DK2018165T3 true DK2018165T3 (da) 2011-08-01

Family

ID=36808846

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07717861.4T DK2018165T3 (da) 2006-01-13 2007-01-12 Dimere agonistforbindelser af FGF-receptorer

Country Status (36)

Country Link
US (1) US9120819B2 (da)
EP (1) EP2018165B1 (da)
JP (1) JP5286088B2 (da)
KR (1) KR101378220B1 (da)
CN (1) CN101384258B (da)
AR (1) AR059001A1 (da)
AT (1) ATE505188T1 (da)
AU (1) AU2007204252B2 (da)
BR (1) BRPI0707132A2 (da)
CA (1) CA2633057C (da)
CR (1) CR10097A (da)
CY (1) CY1111688T1 (da)
DE (1) DE602007013889D1 (da)
DK (1) DK2018165T3 (da)
EA (1) EA015046B1 (da)
EC (1) ECSP088592A (da)
ES (1) ES2364857T3 (da)
FR (1) FR2896247B1 (da)
HN (1) HN2008001067A (da)
HR (1) HRP20110514T1 (da)
IL (1) IL192403A (da)
JO (1) JO2659B1 (da)
MA (1) MA30214B1 (da)
MX (1) MX2008009010A (da)
NO (1) NO20083406L (da)
NZ (1) NZ569631A (da)
PE (1) PE20071115A1 (da)
PL (1) PL2018165T3 (da)
PT (1) PT2018165E (da)
RS (1) RS51872B (da)
SI (1) SI2018165T1 (da)
TN (1) TNSN08250A1 (da)
TW (1) TWI386408B (da)
UA (1) UA95469C2 (da)
WO (1) WO2007080325A1 (da)
ZA (1) ZA200806547B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2883286B1 (fr) * 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
EP2270043A1 (en) 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
FR2962438B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
FR2962437B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
US8901341B2 (en) 2011-02-11 2014-12-02 Bezwada Biomedical, Llc Amino acid derivatives and absorbable polymers therefrom
US9446175B2 (en) 2011-06-03 2016-09-20 Yale University Compositions and methods for treating and preventing neointimal stenosis
FR2982261B1 (fr) * 2011-11-04 2014-06-13 Galderma Res & Dev Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique
FR2985258A1 (fr) 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
FR2985257B1 (fr) * 2011-12-28 2014-02-14 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
FR2985185B1 (fr) * 2012-01-04 2013-12-27 Sanofi Sa Utilisation en therapeutique de derives d'imidazopyridine
JP6806562B2 (ja) 2013-03-15 2021-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｅＩＦ２α経路の調節因子
EP2994130A4 (en) * 2013-05-06 2017-02-22 Bush, Andrew B. Fgf modulation of in vivo antibody production and humoral immunity
ES3038189T3 (en) 2015-12-11 2025-10-10 Res Inst Nationwide Childrens Hospital Systems and methods for optimized patient specific tissue engineering vascular grafts
WO2025045826A1 (en) 2023-08-25 2025-03-06 The Cultivated B. Gmbh Compounds for activation of fgfr1 signaling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
WO2003094956A1 (en) 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
AU2007204252B2 (en) 2012-05-24
JP5286088B2 (ja) 2013-09-11
MX2008009010A (es) 2008-09-25
FR2896247B1 (fr) 2008-02-29
RS51872B (sr) 2012-02-29
BRPI0707132A2 (pt) 2011-04-19
ZA200806547B (en) 2009-12-30
JP2009523160A (ja) 2009-06-18
SI2018165T1 (sl) 2011-08-31
CR10097A (es) 2008-10-29
TW200738708A (en) 2007-10-16
WO2007080325A8 (fr) 2008-10-23
EP2018165B1 (fr) 2011-04-13
CY1111688T1 (el) 2015-10-07
PL2018165T3 (pl) 2011-09-30
CA2633057C (fr) 2014-10-21
HN2008001067A (es) 2011-01-24
CA2633057A1 (fr) 2007-07-19
IL192403A0 (en) 2008-12-29
DE602007013889D1 (de) 2011-05-26
FR2896247A1 (fr) 2007-07-20
NO20083406L (no) 2008-10-13
MA30214B1 (fr) 2009-02-02
AU2007204252A1 (en) 2007-07-19
TNSN08250A1 (en) 2009-10-30
AR059001A1 (es) 2008-03-05
TWI386408B (zh) 2013-02-21
WO2007080325A1 (fr) 2007-07-19
EP2018165A1 (fr) 2009-01-28
CN101384258B (zh) 2013-06-26
KR101378220B1 (ko) 2014-03-27
ES2364857T3 (es) 2011-09-15
UA95469C2 (ru) 2011-08-10
CN101384258A (zh) 2009-03-11
US20090069368A1 (en) 2009-03-12
ATE505188T1 (de) 2011-04-15
EA015046B1 (ru) 2011-04-29
HRP20110514T1 (hr) 2011-08-31
PT2018165E (pt) 2011-07-14
JO2659B1 (en) 2012-06-17
KR20090006060A (ko) 2009-01-14
IL192403A (en) 2012-10-31
US9120819B2 (en) 2015-09-01
ECSP088592A (es) 2008-08-29
PE20071115A1 (es) 2007-12-14
HK1130009A1 (en) 2009-12-18
EA200870167A1 (ru) 2009-12-30
NZ569631A (en) 2011-04-29

Similar Documents

Publication Publication Date Title
LTPA2020501I1 (lt) Pakeistieji enaminokarbonilo junginiai
LTC2379069I2 (lt) S1p receptoriaus agonisto dozavimas
PT2018165E (pt) Compostos diméricos agonistas dos receptores dos fgf
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
ATE524460T1 (de) Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
EP2044055A4 (en) amide compounds
DK2066628T3 (da) 2-Phenylindoler som antagonister af prostaglandin-D2-receptorer
DK2089382T3 (da) Substituerede diazepan-forbindelser som orexin-receptor-antagonister
HRP20151108T1 (xx) Antagonisti nogo-receptora
HRP20170246T1 (hr) Režim doziranja za selektivni agonist s1p1-receptora
EP2004654A4 (en) Kinase Antagonists
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
DK2185567T3 (da) Substituerede bicyclolactam-forbindelser
DK2046740T3 (da) Forbindelser med CRTH2-antagonistisk virkning
DK2092722T3 (da) VoIP-konference
EP2079466A4 (en) SUBSTITUTED INDOLE COMPOUNDS
DE602007012330D1 (de) Beschichtungszusammensetzung
ATE539056T1 (de) Piperidinderivate als agonisten muskariner rezeptoren
DK2117542T3 (da) Kombinationer af beta-2-adrenoceptor-agonistisk benzothiazolon
ATE524477T1 (de) Aziridinylepothilonverbindungen
DK1981875T3 (da) Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
DK2089367T3 (da) Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
EP2023920A4 (en) Cannabinoid receptor Antagonist / inverse agonists
CR10562A (es) Nuevos derivados de piridazina
DK1979314T3 (da) Indolsulfonamidmodulatorer af progesteronreceptorer